FINANCIAL STATEMENTS (UNAUDITED)

For the 1st quarter ended 30th September, 2026

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur,

Dhaka-1207, Bangladesh.

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED)

As at 30 September 2026

Amount in Taka

	Notes	30 September 2026	30 June 2026
ASSETS:			
Non-Current Assets:		**7,677,737,653**	**7,507,719,201**
Property, Plant and Equipment	04.A	3,321,842,490	2,638,512,167
Capital Work-In-Progress	05.1.A	4,286,202,010	4,785,835,577
Right-of-Use Assets	05.2	6,201,133	8,268,178
Advances, Deposits & Prepayments	10.A.1	22,423,325	33,965,070
Financial Assets	06.A	41,068,694	41,138,209
Current Assets :		**3,597,121,687**	**3,302,659,427**
Financial Assets	08.A	22,500,000	22,500,000
Inventories	08.2	2,026,519,795	1,972,382,955
Trade and Other Receivables	09.A	247,392,451	189,774,389
Advances, Deposits & Prepayments	10 A.1	906,071,135	820,696,923
Cash & Cash Equivalents	11.A	394,638,306	297,305,160
TOTAL ASSETS		**11,274,859,340**	**10,810,378,628**
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Shareholders' Equity:		**4,894,528,625**	**4,655,848,970**
		4,755,798,337	**4,516,608,247**
Share Capital	12	312,436,270	312,436,270
Tax Holiday Reserve	13	4,392,110	4,392,110
FVOCI Reserve	14	(20,574,273)	(20,511,709)
Retained Earnings	15.A	4,459,544,229	4,220,291,576
Non Controlling Interest	15.B	138,730,289	139,240,723
LIABILITIES:			
Non-Current Liabilities:		**1,283,636,912**	**1,290,768,614**
Long Term Finance	16.A	1,194,896,336	1,197,232,556
Employee Benefit Obligations	17.A	1,038,888	507,721
Deferred Tax Liabilities	19.A	87,701,688	93,028,338
Current Liabilities:		**5,096,693,802**	**4,863,761,044**
Short Term Finance	20.A	3,050,377,776	2,636,364,359
Current Portion of Long Term Finance	21	129,401,243	172,534,991
Trade and Other Payables	22 A	1,077,884,052	1,307,039,568
Unclaimed Dividend	22.B	27,901,170	28,040,490
Provision for Corporate Tax	23.A	811,129,560	719,781,636
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		**11,274,859,340**	**10,810,378,629**
Net Assets Value (NAV) Per Share	31 A	152.22	144.56

Chief Financial Officer | Company Secretary | Director

Managing Director | Chairman

Dated, Dhaka .
08 November 2026

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)

For the 1st quarter ended 30 September 2026

Amount in Taka

	Notes	From 1 July 2026 to 30 September 2026	From 1 July 2025 to 30 September 2025
REVENUE	24.A	3,983,089,021	3,716,673,149
Cost of goods sold	24.1	(2,306,125,960)	(2,176,471,586)
GROSS PROFIT		**1,676,963,061**	**1,540,201,563**
OPERATING EXPENSES		**(1,307,753,534)**	**(1,193,920,288)**
Administrative expenses	25.A	(76,360,450)	(69,896,894)
Selling & Distribution expenses	26.A	(1,231,393,084)	(1,124,023,394)
OPERATING PROFIT		**369,209,528**	**346,281,276**
Other income		8,591,217	9,448,212
PROFIT BEFORE FINANCING AND INCOME TAXES		**377,800,745**	**355,729,488**
Financial charges	34.A	(36,102,094)	(26,706,687)
PROFIT BEFORE WPPF & TAX		**341,698,650**	**329,022,801**
Workers' P.P. fund & welfare fund	27.A	(16,928,186)	(16,099,695)
PROFIT BEFORE TAX		**324,770,464**	**312,923,106**
Income tax expenses	28.A	(86,028,245)	(91,997,337)
NET PROFIT AFTER TAX		**238,742,219**	**220,925,769**
Profit/(Loss) Attributable to:			
Owner of the Company		239,252,653	221,226,529
Non-controlling interest	35.01	(510,434)	(300,760)
		238,742,219	220,925,769
Other Comprehensive Income:			
Change in FVOCI Financial Assets	29	(69,515)	(3,304,674)
Related Deferred tax		6,952	330,467
Total other comprehensive income for the period, net of tax		(62,564)	(2,974,207)
Total comprehensive income for the period		**238,679,655**	**217,951,562**
Total Comprehensive income Attributable to:			
Owner of the Company		239,190,090	218,252,322
Non-controlling interest		(510,434)	(300,760)
		238,679,655	**217,951,562**
Earnings Per Share (EPS)	30.A	**7.66**	**7.08**
Number of Shares used to Compute EPS		**31,243,627**	**31,243,627**

Chief Financial Officer | Company Secretary | Director

Managing Director | Chairman

Dated, Dhaka . .
08 November 2026

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

For the 1st quarter ended 30 September 2026

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Non Controlling Interest	Total
Balance as at 1 July 2025	**312,436,270**	**4,392,110**	**(15,544,332)**	**3,625,617,615**	**70,946,596**	**3,997,848,260**
Statement of profit or loss and other comprehensive Income-2025-26	-	-	(4,967,378)	794,633,174	(1,705,873)	787,959,923
Dividend for the period 30 June 2025 (Cash - 64.00%)				(199,959,213)	-	(199,959,213)
Issued during the year					70,000,000	70,000,000
Balance as at 30 June 2025	**312,436,270**	**4,392,110**	**(20,511,710)**	**4,220,291,575**	**139,240,723**	**4,655,848,970**
Statement of profit or loss and other Comprehensive Income for period ended 30 September 2026			(62,564)	239,252,653	(510,434)	238,679,655
Balance as at 30 September 2026	**312,436,270**	**4,392,110**	**(20,574,274)**	**4,459,544,229**	**138,730,289**	**4,894,528,625**

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

For the 1st quarter ended 30 September 2025

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Non Controlling Interest	Total
Balance as at 1 July 2024	**312,436,270**	**4,392,110**	**(8,610,721)**	**3,189,263,114**	**35,879,718**	**3,533,360,493**
Statement of profit or loss and other comprehensive Income-2024-25		-	(6,933,611)	633,189,350	66,877	626,322,617
Dividend for the period 30 June 2024 (Cash - 63.00%)				(196,834,850)	-	(196,834,850)
Issue during the year					35,000,000	35,000,000
Balance as at 30 June 2025	**312,436,270**	**4,392,110**	**(15,544,332)**	**3,625,617,614**	**70,946,596**	**3,997,848,260**
Statement of profit or loss and other Comprehensive Income for period ended 30 September 2025			(2,974,207)	221,226,529	(300,760)	217,951,562
Balance as at 30 September 2025	**312,436,270**	**4,392,110**	**(18,518,539)**	**3,846,844,143**	**70,645,836**	**4,215,799,822**

Chief Financial Officer | Company Secretary | Director

Managing Director | Chairman

Dated, Dhaka .
08 November 2026

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

For the 1st quarter ended 30 September 2026

	Amount in Taka	
	From 1 July 2026 to 30 September 2026	From 1 July 2025 to 30 September 2025
Cash Flows From Operating Activities:		
Received from revenue and others	3,926,163,275	3,673,093,767
Payment for operation, expenses & others	(3,830,764,221)	(3,454,296,015)
Miscellaneous income	5,240,041	301,460
Cash generated from operations	**100,639,095**	**219,099,212**
Income tax paid	(51,136,034)	(22,296,605)
Payment for Financial charges	(36,052,701)	(26,155,287)
Net cash generated from operating activities	**13,450,360**	**170,647,320**
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(284,662,964)	(255,717,208)
Net cash used in investing activities	**(284,662,964)**	**(255,717,208)**
Cash Flows From Financing Activities:		
Payment of dividend	(139,320)	(2,162,847)
Long term finance received/(paid) from bank (Net)	(2,336,220)	16,430,621
Short term finance received/(paid) from bank (Net)	370,879,670	93,819,905
Net cash from financing activities	**368,404,130**	**108,087,679**
Increase/(decrease) in cash and cash equivalents	97,191,527	23,017,791
Opening cash and cash equivalents	297,305,158	314,903,147
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	141,622	2,715,767
Closing cash and cash equivalents	**394,638,306**	**340,636,705**
NOCFPS (Note 32.A)	**0.43**	**5.46**

Chief Financial Officer | Company Secretary | Director

Managing Director | Chairman

Dated, Dhaka .
08 November 2026

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF FINANCIAL POSITION (UNAUDITED)
As at 30 September 2026

	Notes	30 September 2026	30 June 2026
		Amount in Taka	
ASSETS:			
Non-Current Assets:		**7,762,258,991**	**7,461,742,876**
Property, Plant and Equipment	04	2,394,271,409	2,389,616,834
Capital Work-In-Progress	05.1	3,989,374,959	3,779,835,116
Right of Use Assets	05.2	6,201,133	8,268,178
Financial Assets	06	12,068,694	12,138,209
Advances, Deposits & Prepayments	10.1	22,173,325	33,715,070
Investment in Subsidiary	07	1,338,169,470	1,238,169,470
Current Assets :		**3,019,161,629**	**2,851,217,065**
Financial assets	08	22,500,000	22,500,000
Inventories	08.1	1,761,985,161	1,738,794,887
Trade and Other Receivables	09	239,230,055	180,245,054
Advances, Deposits & Prepayments	10.1	809,461,827	749,291,153
Cash & Cash Equivalents	11	185,984,586	160,385,971
TOTAL ASSETS		**10,781,420,620**	**10,312,959,941**
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Shareholders' Equity:		**4,761,423,144**	**4,520,143,263**
Share Capital	12	312,436,270	312,436,270
Tax Holiday Reserve	13	4,392,110	4,392,110
FVOCI Reserve	14	(20,574,273)	(20,511,709)
Retained Earnings	15	4,465,169,037	4,223,826,592
LIABILITIES:			
Non-Current Liabilities:		**1,077,452,361**	**1,081,580,746**
Long Term Finance	16	994,768,217	990,125,690
Employee Benefit Obligations	17	1,038,888	507,721
Deferred Tax Liabilities	18	81,645,256	90,947,336
Current Liabilities:		**4,942,545,114**	**4,711,235,933**
Short Term Finance	20	3,021,071,590	2,607,058,173
Current Portion of Long Term Finance	21	129,401,243	172,534,991
Trade and Other Payable	22	1,014,066,299	1,238,363,259
Unclaimed Dividend	22.B	27,901,170	28,040,490
Provision for Corporate Tax	23	750,104,811	665,239,020
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		**10,781,420,620**	**10,312,959,942**
Net Assets Value (NAV) Per Share	31	**152.40**	**144.67**

Chief Financial Officer | Company Secretary | Director

Managing Director | Chairman

Dated, Dhaka .
08 November 2026

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)

For the 1st quarter ended 30 September 2026

Amount in Taka

	Notes	From 1 July 2026 to 30 September 2026	From 1 July 2025 to 30 September 2025
REVENUE	24	3,555,965,873	3,314,047,063
Cost of goods sold	24.B	(2,066,913,123)	(1,950,954,106)
GROSS PROFIT		**1,489,052,750**	**1,363,092,957**
OPERATING EXPENSES		**(1,128,783,111)**	**(1,029,959,602)**
Administrative expenses	25	(56,927,642)	(54,957,161)
Selling & Distribution expenses	26	(1,071,855,469)	(975,002,441)
OPERATING PROFIT		**360,269,640**	**333,133,356**
Other income		8,591,217	9,448,212
PROFIT BEFORE FINANCING AND INCOME TAXES		**368,860,857**	**342,581,568**
Financial charges	34	(36,102,094)	(26,706,687)
PROFIT BEFORE WPPF & TAX		**332,758,763**	**315,874,881**
Workers' P.P. fund & welfare fund	27	(15,845,655)	(15,041,661)
PROFIT BEFORE TAX		**316,913,107**	**300,833,220**
INCOME TAX EXPENSES	28	**(75,570,662)**	**(85,460,508)**
NET PROFIT AFTER TAX		**241,342,445**	**215,372,712**
Other Comprehensive Income:			
Change in FVOCI Financial Assets	29	(69,515)	(3,304,674)
Related Deferred tax		6,952	330,467
Total other comprehensive income for the period, net of tax		(62,564)	(2,974,207)
Total comprehensive income for the period		**241,279,882**	**212,398,506**
Earnings Per Share (EPS)	30	**7.72**	**6.89**
Number of Shares used to Compute EPS		**31,243,627**	**31,243,627**

Chief Financial Officer | Company Secretary | Director

Dated, Dhaka .
08 November 2026

Managing Director | Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF CHANGES IN EQUITY (UNAUDITED)
For the 1st quarter ended 30 September 2026

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Total
Balance as at 1 July 2025	**312,436,270**	**4,392,110**	**(15,544,332)**	**3,631,099,007**	**3,932,383,056**
Statement of profit or loss and other comprehensive Income-2025-26			(4,967,378)	792,686,798	787,719,420
Dividend for the period 30 June, 2025 (Cash -64.00%)				(199,959,213)	(199,959,213)
Balance as at 30 June 2026	**312,436,270**	**4,392,110**	**(20,511,710)**	**4,223,826,593**	**4,520,143,263**
Statement of profit or loss and other Comprehensive Income for period ended 30 September 2026			(62,564)	241,342,445	241,279,882
Balance as at 30 September 2026	**312,436,270**	**4,392,110**	**(20,574,274)**	**4,465,169,038**	**4,761,423,144**

STATEMENT OF CHANGES IN EQUITY (UNAUDITED)
For the 1st quarter ended 30 September 2025

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Total
Balance as at 1 July 2024	**312,436,270**	**4,392,110**	**(8,610,721)**	**3,167,771,833**	**3,475,989,493**
Statement of profit or loss and other comprehensive Income-2024-25			(6,933,611)	660,162,024	653,228,413
					-
Dividend for the period 30 June, 2024 (Cash -63.00%)				(196,834,850)	(196,834,850)
					-
Balance as at 30 June 2025	**312,436,270**	**4,392,110**	**(15,544,332)**	**3,631,099,008**	**3,932,383,056**
Statement of profit or loss and other Comprehensive Income for period ended 30 September 2025			(2,974,207)	215,372,712	212,398,506
Balance as at 30 September 2025	**312,436,270**	**4,392,110**	**(18,518,539)**	**3,846,471,720**	**4,144,781,562**

Chief Financial Officer | Company Secretary | Director

Managing Director | Chairman

Dated, Dhaka .
08 November 2026

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF CASH FLOWS (UNAUDITED)
For the 1st quarter ended 30 September 2026

Amount in Taka

	From 1 July 2026 to 30 September 2026	From 1 July 2025 to 30 September 2025
Cash Flows From Operating Activities:		
Received from revenue and others	3,497,673,187	3,268,895,049
Payment for operation, expenses & others	(3,409,824,408)	(3,053,521,792)
Miscellaneous income	5,240,041	301,460
Cash generated from continuing operations	**93,088,820**	**215,674,717**
Income tax paid	(50,136,034)	(21,296,605)
Payment for Financial charges	(36,052,701)	(26,155,287)
Net cash provided by operating activities	**6,900,085**	**168,222,825**
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(256,825,970)	(199,740,649)
Investment in Subsidiary	(100,000,000)	(10,000,000)
Net cash used in investing activities	**(356,825,970)**	**(209,740,649)**
Cash Flows From Financing Activities:		
Payment of dividend	(139,320)	(2,162,847)
Long term finance received/(paid) from bank (Net)	4,642,528	8,977,822
Short term finance received/(paid) from bank (Net)	370,879,670	107,699,905
Net cash from financing activities	**375,382,878**	**114,514,880**
Increase/(decrease) in cash and cash equivalents	25,456,994	72,997,056
Opening cash and cash equivalents	160,385,971	180,681,788
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	141,622	2,715,767
Closing cash and cash equivalents	**185,984,586**	**256,394,611**
NOCFPS (Note 32)	**0.22**	**5.38**

Chief Financial Officer | Company Secretary | Director

Managing Director | Chairman

Dated, Dhaka .
08 November 2026

SELECTED EXPLANATORY NOTES:

1.1 The company and the group

The IBN SINA Pharmaceutical Industry PLC (the "Company") was incorporated in Bangladesh on 22 December 1983 under the Companies Act, 1913 (replaced by the Companies Act 1994) and it was converted into a Public Limited Company in 1989.

The registered office of the company is at Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207. The Company is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE).

As the 99.99% shareholder of The IBN SINA API Industry Ltd., 99.99% The IBN SINA Natural Medicine Ltd. and 65% The IBN SINA Polymer Industry Ltd.; The IBN SINA Pharmaceutical Industry PLC started its operation as a group company from 16 September 2019. Hereinafter it is referred as the group as and where applicable for the purpose of preparing consolidated financial statements.

1.2 Nature of business

The Company involves in production of pharmaceutical drugs and natural medicines and selling them in both local and international market.

2 Basis of preparation

2.1 Statement of compliance

These interim financial statements have been prepared in accordance with the International Accounting Standard IAS 34: Interim Financial Reporting, the Companies Act 1994, the Securities and Exchange Rules 2020, Financial Reporting Act 2015, relevant guidelines issued by Bangladesh Securities and Exchange Commission ("BSEC") and other applicable laws and regulations in Bangladesh.

The financial statements have been prepared on a historical cost basis, except for financial assets that have been measured at fair value where applicable. The financial statements provide comparative information in respect of the previous period and have been prepared on going concern basis. The interim financial statements should be read in conjunction with The IBN SINA Pharmaceutical Industry PLC's annual statutory financial statements as at 30 June 2026.

2.2 Date of authorisation

The interim financial statements were authorised for issue by the Board of Directors on 08 November 2026 for publication.

2.3 Functional and presentation currency

The financial statements are presented in Bangladeshi Taka (BDT), which is both functional and presentation currency of The IBN SINA Pharmaceutical Industry PLC.

2.4 Significant accounting policies

The same accounting policies and methods of computation have been followed in these interim financial statements as were applied in the preparation of the audited financial statements of The IBN SINA Pharmaceutical Industry PLC as at and for the year ended 30 June 2026.

3 Significant Deviations

3.1 EARNINGS PER SHARE (EPS):

Earnings per share has been calculated based on number of shares outstanding for the period ended 30 September 2026 and profit for the same period. The number of shares outstanding for the period was 31,243,627. Earnings per share for the corresponding period of 2025 has also been calculated based on 31,243,627 shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

3.2 SUBSEQUENT EVENTS:

No material events occurred after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.

3.3 INCREASE IN EARNINGS PER SHARE (EPS):

As a result of increase in sales revenue and profit , EPS has been increased during current period over last reporting period.

3.4 DECREASE IN NET OPERATING CASH FLOW PER SHARE (NOCFPS):

Net operating cash flow per share (NOCFPS) decreased during current period over last reporting period due to increase in payment for cost & expenses & others.

3.5 INCOME TAX:

Payment of income tax increased due to increase in revenue and net profit. Advance income tax also increased due to payment for quarterly installment.

3.6 PAYMENT FOR FIXED ASSETS:

Payment for purchases of fixed assets increased due to increase in addition of fixed assets during this reporting period.

3.7 Other income decreased during the period due to decrease in revenue from toll production charge.

3.8 Payment for short term loan increased due to meet up business need.

3.9 FINANCE CHARGE:

Finance charge during the reporting period increased due to increase of long term loan.

3.10 INCREASE IN REVENUE:

The main objective of the company is to increase revenue which is essential for survival in the market. Due to increase in demand for the company's product in market, revenue has been increased during current period over last reporting period.

3.11 CASH FLOWS FROM INVESTING ACTIVITIES:

Cash flows from investing activities increased during the reporting period due to increased payment made for purchase of fixed assets.

3.12 SHORT TERM FINANCE:

Short term finance increased during the period due to increase in import of raw materials under working capital financing arrangement with bank.

3.13 Previous period figures have been re-arranged to conform to current period presentation, where considered necessary.

	Amount in Taka	
	30 September 2026	30 June 2026
04. PROPERTY, PLANT AND EQUIPMENT:		
Cost :		
Opening balance	4,306,293,623	4,169,069,419
Addition during the period	48,786,126	137,224,204
Disposal/Adjustment during the period	(1,500,000)	-
Closing balance	**4,353,579,749**	**4,306,293,623**
Accumulated Depreciation:		
Opening balance	1,916,676,789	1,737,415,883
Charged during the period	43,820,103	179,260,907
Disposal/Adjustment during the period	(1,188,552)	-
Closing balance	**1,959,308,339**	**1,916,676,789**
Closing balance of written Down Value (WDV)	**2,394,271,409**	**2,389,616,834**

i.The factory land and land development (803 decimal) and building are pledged as security for long term and short term bank finance of the company.

ii. New building construction in the Factory Shafipur has been completed and transferred from CWIP to PPE.

04 A. CONSOLIDATED PROPERTY, PLANT AND EQUIPMENT:		
The IBN SINA Pharmaceutical Industry PLC	2,394,271,409	2,389,616,834
The IBN SINA API Industry Ltd.	841,209,860	164,672,352
The IBN SINA Polymer Industry Ltd.	2,359,562	2,380,977
The IBN SINA Natural Medicine Ltd.	84,001,659	81,842,005
	3,321,842,490	**2,638,512,168**
05.1 CAPITAL WORK-IN-PROGRESS		
A) Construction work-in-progress (Building)		
Opening balance	912,642,992	711,323,283
Addition during the period	50,264,905	201,319,709
Less: Transferred to PPE	-	-
	962,907,897	**912,642,992**
B) Machinery in transit and installation		
Opening balance	2,839,737,033	398,469,652
Addition during the period/year	156,028,214	2,710,341,137
Less: Transit closed during the period/year	-	(269,073,756)
	2,995,765,247	2,839,737,033
Other Goods-in-Transit	30,701,816	27,455,091
	3,989,374,959	**3,779,835,116**

i) A new building is being constructed to increase the overall production capacity of The IBN SINA Pharmaceutical Industry PLC.

ii) The amount of machinery in transit represents the amount for opening the LC for the procurement of machineries for newly constructed factory building and increasing production capacity of existing factory which have not received yet .

iii) Capitalisation rate used is 7.5%

iv. New building construction in the Factory Shafipur has been completed and transferred from CWIP to PPE.

05.1A CONSOLIDATED CAPITAL WORK-IN-PROGRESS		
A) Construction work-in-progress (Building)		
Opening balance	1,280,918,499	939,492,119
Addition during the period/year	50,351,715	341,426,379
Less: Transferred to PPE	(82,375,751)	-
Closing balance	**1,248,894,463**	**1,280,918,499**
B) Machinery in transit and installation		
Opening balance	3,477,461,987	946,837,388
Addition during the period/year	174,884,729	2,799,698,356
Less: Transit closed during the period/year	(645,740,984)	(269,073,756)
Closing balance	**3,006,605,732**	**3,477,461,987**
Other Goods-In-Transit	30,701,816	27,455,091
	4,286,202,010	**4,785,835,577**
05.2 RIGHT OF USE ASSETS:		
Opening balance	130,252,602	130,252,602
Closing balance	**130,252,602**	**130,252,602**
Accumulated Depreciation:		
Opening balance	121,984,424	97,179,891
Charged during the period	2,067,044	24,804,533
Disposal/Adjustment during the year	-	-
Closing balance	**124,051,469**	**121,984,424**
Closing balance of Written Down Value (WDV)	**6,201,133**	**8,268,178**

		Amount in Taka	
		30 September 2026	30 June 2026
06.	**FINANCIAL ASSESTS (NON-CURRENT PORTION):**		
	Investment in marketable securities (FVOCI)		
	Exim Bank PLC	1,140,000	1,140,000
	First Security Islami Bank PLC	3,896,900	3,896,900
	Shahjalal Islami Bank PLC	1,802,500	1,854,000
	Al-Arafah Islami Bank PLC	1,633,065	1,676,325
	Social Islami Bank PLC	520,929	520,929
	Islami Bank Bangladesh PLC (IBBPLC) in MPB	3,075,300	3,050,055
		12,068,694	**12,138,209**

The above investment in marketable securities are designated as Fair Value thought other comprehensive income by the management. These are measured at fair value and presented as non-current asset. Unrealized gain/(loss) from the above investment were recognized in other comprehensive income.

06.A	**CONSOLIDATED FINANCIAL ASSESTS (NON-CURRENT PORTION):**		
	Exim Bank PLC	1,140,000	1,140,000
	First Security Islami Bank PLC	3,896,900	3,896,900
	Shahjalal Islami Bank PLC	1,802,500	1,854,000
	Al-Arafah Islami Bank PLC	1,633,065	1,676,325
	Social Islami Bank PLC	520,929	520,929
	Islami Bank Bangladesh PLC (IBBPLC) in MPB	3,075,300	3,050,055
	Investment in API Industrial Park Services Ltd.	29,000,000	29,000,000
		41,068,694	**41,138,209**
07	**INVESTMENT IN SUBSIDIARY**		
	The IBN SINA API Industry Ltd.	839,999,800	799,999,800
	The IBN SINA Natural Medicine Ltd.	238,169,670	238,169,670
	The IBN SINA Polymer Industry Ltd.	260,000,000	200,000,000
		1,338,169,470	**1,238,169,470**

i) The IBN SINA API Industry Ltd. is a 99.99% owned subsidiary company.

ii) The IBN SINA Natural Medicine Ltd. is a 99.99% owned subsidiary company.

iii) The IBN SINA Polymer Industry Ltd. is a 65% owned subsidiary company.

08.	**FINANCIAL ASSESTS (CURRENT PORTION):**		
	Opening balance (Investment in MTD)	22,500,000	22,500,000
		22,500,000	**22,500,000**
08.A	**CONSOLIDATED FINANCIAL ASSESTS (CURRENT PORTION):**		
	Investment in MTD	22,500,000	22,500,000
		22,500,000	**22,500,000**
08.1	**INVENTORIES:**		
	Raw materials	717,065,057	713,243,317
	Packing materials	270,936,884	269,533,870
	Work-in-process	108,113,345	105,219,105
	Finished goods	349,215,206	344,256,222
	Physicians' samples	6,680,405	6,578,305
	Pad & literature	4,840,393	4,719,383
	Spares & stores	450,789	429,379
	Indirect materials	519,156	515,942
	Printing & stationery	459,282	448,072
	Laboratory chemicals	262,775	261,565
	Material in Transit	303,441,870	293,589,728
		1,761,985,161	**1,738,794,887**

i) The inventory quantity can not be disclosed as some of material contain in liter, some are in pieces , some are in box and some are in kg, gram, milligram and ton as such quantity can not be inserted.

ii) There is no damage goods or slow moving item in the inventory list.

iii) As part of loan condition all of the company's inventory are pledged as security for loan finance of the company.

iv) Inventory for Raw materials , Packing materials, Work In Process, Finished goods and pad & literature changed during the period for ensuring smooth supply of products.

	Amount in Taka	
	30 September 2026	30 June 2026
08.2. CONSOLIDATED INVENTORIES:		
Raw materials	773,968,995	799,860,851
Packing materials	295,390,888	295,680,022
Work-in-process	119,373,315	126,653,151
Finished goods	448,738,001	440,506,971
Physicians' samples	12,897,689	9,717,892
Pad & literature	4,840,393	4,719,383
Spares & stores	450,789	429,379
Indirect materials	519,156	515,942
Printing & stationery	459,282	448,072
Laboratory chemicals	262,775	261,565
Material in Transit	369,618,513	293,589,728
	2,026,519,795	**1,972,382,955**
09. TRADE AND OTHER RECEIVABLES:		
Trade receivable (net off bad debt provision)	233,229,365	170,988,026
Receivable from provident fund (PF)	-	602,059
Dividend receivable	341,496	341,496
Profit receivable from MTD	5,659,194	4,966,878
Other receivable-toll charge	-	3,346,594
	239,230,055	**180,245,053**
09.A CONSOLIDATED TRADE AND OTHER RECEIVABLES:		
Trade receivable (net off bad debt provision)	241,391,761	180,517,362
Receivable from provident fund (PF)	-	602,059
Dividend receivable	341,496	341,496
Profit receivable from MTD	5,659,194	4,966,878
Other receivable-toll charge	-	3,346,594
	247,392,451	**189,774,389**

i) Amount are receivables from customers mainly different hospitals, medical colleges, clinics, diagnostic centers. No amount was due by the directors (including the Managing Director), managers and other officers of the company or any of them either severally or jointly with any other person.

10. ADVANCES, DEPOSITS & PREPAYMENTS :

This is recoverable in cash or for value to be received and consists of :

a. Advances against-		
Salary	7,389,899	6,102,581
Expenses/works/others	10,193,289	12,433,414
Depot rent	6,253,187	6,816,187
Motor cycles-to employees	37,235,225	66,216,715
Building (Flat) - Concord Lily Height'S	130,030,514	105,000,000
Others	706,533	706,533
	191,808,647	**197,275,431**
b. Income tax-		
Opening balance	565,149,543	374,539,128
Addition	50,136,034	190,610,415
Adjusted during the period	-	-
	615,285,577	**565,149,543**
c. Deposits -		
Security money	**24,134,111**	**20,580,535**
d. Pre payments -		
Value Added Tax	406,817	715
	831,635,152	**783,006,223**
10.1 MATURITY ANALYSIS:		
Realisable/adjustable within one year.	809,461,827	749,291,153
Realisable/adjustable after one year.	22,173,325	33,715,070
	831,635,152	**783,006,223**

i) The company did not give any advance, deposit and prepayment to the director's of the company, subsidiary, associates and other connected party and employees advances are realised in normal course of business.

ii) Advance against works, salary and motor cycle increased during this year to meet up business needs.

iii) Advance income tax increased during this period to meet up regulatory requirement.

iv) Security money decreased during this year as security money was adjusted by various parties.

	Amount in Taka	
	30 September 2026	30 June 2026
10 A. CONSOLIDATED ADVANCES, DEPOSITS & PREPAYMENTS :		
This is recoverable in cash or for value to be received and consists of :		
a. Advances against-		
Salary	11,011,610	16,459,616
Expenses/works/others	39,582,801	13,573,966
Depot rent	6,253,187	6,816,187
Motor cycles-to employees	51,771,904	78,047,148
Building (Flat) - Concord Lily Height'S	130,030,514	105,000,000
Others	2,975,354	2,991,698
	241,625,370	222,888,615
b. Income tax		
Opening balance	610,137,431	404,148,716
Addition	51,136,034	205,988,714
Adjusted during the period	-	-
	661,273,465	610,137,431
c. Deposits -		
Security money	25,188,808	21,635,232
d. Pre payments -		
Value Added Tax	406,817	715
	928,494,460	854,661,993
10.A.1 MATURITY ANALYSIS:		
Realisable/adjustable within one year.	906,071,135	820,696,923
Realisable/adjustable after one year.	22,423,325	33,965,070
	928,494,460	854,661,993
11. CASH & CASH EQUIVALENTS:		
a. Cash in hand	8,180,151	7,077,597
b. Cash at bank	174,264,435	149,773,374
c. Imprest cash	3,540,000	3,535,000
Closing balance	185,984,586	160,385,971

11.1 CASH AT BANKS:

i) The bank reconciliation was performed at the period end and found in order.
ii) Physical cash counting was taken place at the period end and no surplus or deficit was found.

11 A. CONSOLIDATED CASH & CASH EQUIVALENTS:		
a. Cash in hand	9,672,673	8,616,897
b. Cash at bank	381,295,633	285,023,263
c. Imprest cash	3,670,000	3,665,000
Closing balance	394,638,306	297,305,160
12. SHARE CAPITAL:		
Authorized:		
50,000,000 Ordinary Shares of Tk. 10 each	500,000,000	500,000,000
Issued, Subscribed & Paid-Up :		
31,243,627 Ordinary Shares of Tk. 10 each fully paid up in cash	312,436,270	312,436,270

The Shareholdings consist of :

Holders	No. of Holders	Total Holdings	Percentage
Sponsors	1	13,843,312	44.31%
Institution (I.C.B)	331	5,833,394	18.67%
General Public	12,595	11,566,921	37.02%
	12,927	31,243,627	100.00%

The distribution schedule showing the number of share holders and their share holdings as on 30.09.2026 are as follows:

	Amount in Taka	
	30 September 2026	30 June 2026

Range of Holdings	No. of Holders	Total Holdings	Percentage
Less than 500 shares	9,907	1,723,086	5.51
500 to 5,000 shares	2,130	3,229,553	10.34
5,001 to 10,000 shares	193	1,375,313	4.40
10,001 to 20,000 shares	88	1,205,874	3.86
20,001 to 30,000 shares	23	530,740	1.70
30,001 to 40,000 shares	10	354,440	1.13
40,001 to 50,000 shares	9	406,615	1.30
Above 50,000 shares	42	22,418,006	71.75
	12,402	**31,243,627**	**100.00**

The shares are listed with the Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The shares were quoted at Tk. 318.10 in the Dhaka Stock Exchange Limited as at 30.09.2026 and at Tk. 337.00 in the Chittagong Stock Exchange Limited as at 30.09.2026 respectively.

13. TAX HOLIDAY RESERVE:	**4,392,110**	**4,392,110**

This represents provision made out of profit of Tax Holiday period in accordance with section 45 (2B) and section 46A (2) of Income Tax Ordinance 1984.

14. FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME (FVOCI) RESERVE:

Closing market value of marketable securities	12,068,694	12,138,209
Less: Cost of marketable securities	34,928,997	34,928,997
Unrealized gain before adjustment of deferred tax	**(22,860,303)**	**(22,790,788)**
Less: Deferred tax on unrealized gain (loss)	2,286,030	2,279,079
Net unrealized gain/(loss) on marketable securities	**(20,574,273)**	**(20,511,709)**

15. RETAINED EARNINGS:

Opening Balance	4,223,826,592	3,631,099,007
Dividend paid	-	(199,959,213)
Add : Net profit during the period	241,342,445	792,686,798
	4,465,169,037	**4,223,826,592**

15 A. CONSOLIDATED RETAINED EARNINGS:

Opening Balance	4,220,291,576	3,625,617,615
Dividend paid	-	(199,959,213)
Add: Net profit during the period	239,252,653	794,633,174
	4,459,544,229	**4,220,291,576**

15 B. NON CONTROLLING INTEREST:

The IBN SINA API Industry Ltd.	200	200
The IBN SINA Natural Medicine Ltd.	3,000	3,000
The IBN SINA Polymer Industry Ltd. (Paid by IBN SINA Trust)	140,000,000	140,000,000
Add: Share of Profit/(Loss)	(1,272,911)	(762,477)
	138,730,289	**139,240,723**

16. LONG TERM FINANCE :

i) From Al-Arafah Islami Bank PLC. Secured (Under Hire Purchase Shirkatul Melk-HPSM)	802,765,510	838,907,795
ii) From Pubali Bank PLC (Long Term -H.P.S.M) Pharma	321,403,951	323,752,886
Current maturity transferred to current liability		
iii) From Al-Arafah Islami Bank PLC Secured (Under Hire Purchase Shirkatul Melk)	(129,401,243)	(172,534,991)
LONG TERM FINANCE - net off current maturity	**994,768,217**	**990,125,690**

i) Loan amount represent the amounts which would be due for repayment after 12 (twelve) months from the date of Statement of Financial position @ 13, 12.50% and 11% of profit.
ii) The loan was taken from Al-Arafah Islami Bank PLC and Pubali Bank PLC against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur and hypothecation of all inventories of the company to import capital machinery and motor vehicle under Hire
iii) HPSM is repayable in 84 monthly equal installment.
iv) Currently all of the company's HPSM and other loans are classified as standard by the Bank.
v) The company achieved AA+ rating in long term and ST-1 for short term from Alpha credit rating Ltd.
vi) For construction purpose company has taken loan from Pubali Bank PLC that is why long term loan increased significantly.
vii) Information regarding loan fall due after five years.

Loan fall due from 2 to 5 years	535,177,006	559,271,863
Loan fall due from 6 to more years	459,591,211	430,853,827
	994,768,217	**990,125,690**

16.A CONSOLIDATED LONG TERM FINANCE :

Al-Arafah Islami Bank PLC-Secured (The IBN SINA Pharmaceutical Industry PLC)	994,768,217	990,125,689
Al-Arafah Islami Bank PLC.-Secured (The IBN SINA API Industry Ltd.)	200,128,119	207,106,867
	1,194,896,336	**1,197,232,556**

	Amount in Taka	
	30 September 2026	30 June 2026

17 EMPLOYEE BENEFIT OBLIGATIONS:

Employee Benefit Obligations represents employees gratuity recognized as liability and its the movement is given below:

Opening Balance	507,721	990,546
Provision during the period	37,222,973	117,017,617
Less: Paid during the period	(36,691,805)	(117,500,442)
	1,038,888	**507,721**

17 A. CONSOLIDATED EMPLOYEE BENEFIT OBLIGATIONS:

Opening Balance	507,721	990,546
Provision during the period	37,222,973	156,776,143
Less: Paid during the period	(36,691,805)	(157,258,968)
	1,038,888	**507,721**

17 B. LEASE LIABILITIES

Opening balance	-	23,798,698
Addition during the period	-	-
Finance charge	49,393	1,282,480
Less: Paid during the period	(49,393)	(25,081,178)
Closing balance	-	-
Less : transferred to current maturity	-	-
	-	-

i) The company has lease against its Head Office and its Depot at Mohammadpur and Mirpur, Dhaka respectively.

ii) Lease period is upto 31.10.2026

iii) Advance amount paid Tk. 11,661,000

iv) Monthly adjustment Tk. 50,000

18. DEFERRED TAX LIABILITIES

Deferred tax assets and liabilities have been recognized and measured in accordance with the provisions of IAS 12 Income Taxes. Related deferred tax (expense)/income have been disclosed in note 19. The components of deferred tax assets and liabilities are given below:

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liabilities
Property, plant and equipment	2,394,271,409	1,981,731,951	412,539,458	20.00%	82,507,892
Gratuity	37,730,694	36,691,805	1,038,889	20.00%	207,778
Lease	6,201,133	-	6,201,133	20.00%	1,240,227
Unrealized gain on marketable securities	(22,860,303)	-	(22,860,303)	10.00%	(2,286,030)
Bad Debt provision	123,050		(123,050)	20.00%	(24,610)
As at 30 September 2026	**2,415,465,983**	**2,018,423,756**	**396,796,128**		**81,645,256**
Property, plant and equipment	2,389,616,834	1,921,535,868	468,080,965	20.00%	93,616,193
Gratuity	118,008,163	117,500,442	(507,721)	20.00%	(101,544)
Lease	8,268,178	7,309,133	959,044	20.00%	191,809
Unrealized gain on marketable securities	(22,790,788)	-	(22,790,788)	10.00%	(2,279,079)
Bad Debt provision	2,400,215	-	(2,400,215)	20.00%	(480,043)
As at 30 June 2026	**2,495,502,602**	**2,046,345,444**	**443,341,286**		**90,947,336**

19. DEFERRED TAX (EXPENSES)/INCOME

Closing balance of deferred tax liability	81,645,256	90,947,336
Opening balance of deferred tax liabilities	90,947,336	94,711,750
(a) Total deferred tax expenses/(income)	**(9,302,080)**	**(3,764,414)**
Add: Deferred tax expenses related to other comprehensive income	6,952	551,931
	(9,295,129)	**(3,212,483)**

	Amount in Taka	
	30 September 2026	30 June 2026

19 A. CONSOLIDATED DEFERRED TAX LIABILITIES:

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability
Property, plant and equipment	3,321,842,492	2,884,273,784	437,568,708		88,765,205
Gratuity	37,730,694	36,691,805	1,038,889	20% to 27.50%	207,778
Accrued profit on mtdr	-	-	-		-
Lease	5,397,612	-	5,397,612		1,039,346
Unrealized gain on marketable securities	(22,860,303)	-	(22,860,303)	10.00%	(2,286,030)
Bad Debt provision	123,050	-	(123,050)	20.00%	(24,610)
As at 30 September 2026	**3,342,233,545**	**2,920,965,589**	**421,021,857**		**87,701,688**
Property, plant and equipment	2,638,512,168	2,161,780,901	476,731,266		95,857,055
Gratuity	161,527,536	161,019,815	(507,721)	20% to 27.50%	(101,544)
Accrued profit on mtdr	-	-	-		-
Lease	8,011,893	7,309,133	702,759	10.00%	102,427
Unrealized gain on marketable securities	(22,790,788)	-	(22,790,788)		(2,349,557)
Bad Debt provision	2,400,215	-	(2,400,215)		(480,043)
As at 30 June 2026	2,787,661,024	2,330,109,850	451,735,302		93,028,338

19 B. DEFERRED TAX (EXPENSES)/INCOME

Closing balance of deferred tax liability	87,701,688	93,028,338
Opening balance of deferred tax liabilities	93,028,338	96,462,538
(a) Total deferred tax expenses	**(5,326,650)**	**(3,434,200)**
Add: Deferred tax expenses related to other comprehensive income	6,952	551,931
	(5,319,699)	**(2,882,270)**

20. SHORT TERM FINANCE :

From Al-Arafah Islami Bank PLC - Secured	3,021,071,590	2,607,058,173
(Under Composite facilities LC(MPI/TR/UPAS)		
	3,021,071,590	**2,607,058,173**

i) Loan amount represent the amounts which would be due for repayment within 12 (twelve) months from the date of statement of financial position @ 15% of profit and 0.20% commission per quarter to be paid.
ii) The loan was taken from Al-Arafah Islami Bank PLC against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur and hypothecation of all inventories of the company to import Pharmaceuticals raw materials, imported goods and to purchase business items from local market under Composite investment facilities LC/MPI/MIB/ TR/UPAS/ Baimuajjal agreement.
iii) Short term loan is repayable within twelve months.
iv) Currently all of the company's MPI/UPAS and other loans are classified as standard by the Bank.
v) Short term finance increased significantly due to settlement of short term LCs.

20.A CONSOLIDATED SHORT TERM FINANCE :

a) From Al-Arafah Islami Bank PLC - Secured	3,021,071,590	2,607,058,173
(Under Composite facilities PLC (MPI/TR/UPAS)		
b) The IBN SINA API Industry Ltd.	29,306,186	29,306,186
	3,050,377,776	**2,636,364,359**

21. LONG TERM FINANCE-CURRENT MATURITY:

i) From Al-Arafah Islami Bank PLC-Secured	**129,401,243**	**172,534,991**
(Under Hire Purchase Shirkatul Melk)		

22. TRADE AND OTHER PAYABLES :

Payable to suppliers	577,775,300	705,359,343
Provisions	112,188,627	166,819,427
Accrued expenses	246,317,712	303,940,483
Security money received from employees and others	12,132,585	12,437,585
Workers' profit participation fund & welfare fund	65,652,076	49,806,420
	1,014,066,299	**1,238,363,259**

22.1 PROVISIONS:

Opening balance	166,819,427	187,977,710
Provisions made during the period/year	112,188,627	166,819,427
Provisions used during the period/year	(166,819,427)	(187,977,710)
Closing balance	**112,188,627**	**166,819,427**

i) Payable to suppliers and accured expenses decreased this year to meetup business need.
ii. Accrued expenses decreased du to payment made same bill after reporting period.

	Amount in Taka	
	30 September 2026	30 June 2026
22 A. CONSOLIDATED TRADE AND OTHER PAYABLES :		
Payable to suppliers	585,587,120	760,786,943
Provisions	112,188,627	166,819,427
Accrued expenses	298,067,630	314,015,709
Security money received from employees and others	12,132,585	12,437,585
Workers' profit participation fund & welfare fund	69,908,091	52,979,904
	1,077,884,052	**1,307,039,568**
22.B UNCLAIMED DIVIDEND :		
Opening	28,040,490	42,104,508
Addition	-	199,959,213
Paid to share holders	(139,320)	(214,023,231)
Paid to Capital Market Stabilisation Fund	-	-
	27,901,170	**28,040,490**
22.1.2 UNCLAIMED DIVIDEND :		
Year-wise break-up of the above is as follows :		
2022-23	10,966,874	10,966,874
2023-24	9,897,229	9,905,202
2024-25	7,037,068	7,168,414
	27,901,170	**28,040,490**
23. PROVISION FOR CORPORATE TAX		
Opening balance	665,239,020	458,584,929
Current tax provision	84,865,791	206,654,091
	750,104,811	**665,239,020**
23 A. CONSOLIDATED PROVISION FOR CORPORATE TAX		
Opening balance	719,781,636	495,245,930
Prior year tax assessment adjustment	-	-
Current tax expense	91,347,924	224,535,706
	811,129,560	**719,781,636**

		Amount in Taka	
		From 1 July 2026 to 30 September 2026	From 1 July 2025 to 30 September 2025
24.	**REVENUE:**		
	Local revenue	3,468,887,592	3,267,483,392
	Export revenue	87,078,281	46,563,671
		3,555,965,873	**3,314,047,063**
24.A	**CONSOLIDATED REVENUE:**		
	Local revenue	3,896,010,740	3,670,109,478
	Export revenue	87,078,281	46,563,671
		3,983,089,021	**3,716,673,149**
24.B	**COST OF GOODS SOLD :**		
	Materials	1,755,222,879	1,585,534,517
	Factory Overhead	279,050,852	331,796,015
	Depreciation	32,639,392	33,623,574
		2,066,913,123	**1,950,954,106**
24.1	**CONSOLIDATED COST OF GOODS SOLD:**		
	Materials	1,941,254,318	1,759,461,533
	Factory Overhead	330,623,268	381,735,803
	Depreciation	34,248,374	35,274,250
		2,306,125,960	**2,176,471,586**

i) Cost of materials and expenses incurred for factory overhead during the reporting period increased due to Increase in goods sold and increase in production respectively .

25.	**ADMINISTRATIVE EXPENSES :**		
	Salary, wages & Allowances	36,674,310	33,977,651
	Repairs & Maintenance	2,678,478	2,322,282
	Travelling & Conveyance	1,525,022	1,839,085
	Depreciation	4,969,966	7,098,815
	Other Expenses	11,079,867	9,719,328
		56,927,642	**54,957,161**
25 A.	**CONSOLIDATED ADMINISTRATIVE EXPENSES :**		
	Salary, wages & Allowances	46,689,567	41,564,481
	Repairs & Maintenance	4,108,456	2,452,069
	Travelling & Conveyance	1,692,647	3,058,116
	Research & Development	1,244,137	681,139
	Fees & charges	462,800	177,374
	Depreciation	7,479,401	9,704,681
	Other Expenses	14,683,443	12,259,034
		76,360,450	**69,896,894**

i) Salary, wages & allowance increased due to increase in manpower, gratuity payment and salary revision.

ii) Repairs & Maintenance expense increased due to increase in maintenance of fixed assets to meet business needs.

iii) Travelling & conveyance decreased during the period due to decrease travel.

iv) Research & development expense increased during this period due to meet business needs.

26.	**SELLING & DISTRIBUTION EXPENSES :**		
	Salary, wages & Allowances	597,417,296	546,243,935
	Travelling & Conveyance	5,381,069	1,676,722
	Market Survey & Research and Product development	2,220,233	2,164,437
	Field personnel expenses	154,713,134	154,643,819
	Sample, Literature & Promotional Expenses	97,547,107	94,650,858
	Delivery Expenses	112,849,844	105,114,060
	Depreciation	8,277,790	7,385,114
	Other Expenses	110,533,922	80,089,982
		1,088,940,395	**991,968,927**
	Less: Expenses for INM	(17,084,926)	(16,966,486)
		1,071,855,469	**975,002,441**

Amount in Taka

	From 1 July 2026 to 30 September 2026	From 1 July 2025 to 30 September 2025
26.A CONSOLIDATED SELLING & DISTRIBUTION EXPENSES :		
Salary, wages & Allowances	692,370,717	639,497,900
Travelling & Conveyance	6,732,500	2,902,129
Market Survey & Research and Product development	2,220,233	2,164,437
Field personnel expenses	178,804,837	176,966,471
Sample, Literature & Promotional Expenses	116,390,137	105,387,371
Delivery Expenses	112,849,844	105,114,060
Depreciation	8,672,114	7,509,138
Other Expenses	113,352,702	84,481,890
	1,231,393,084	**1,124,023,394**

i) Salary, wages & allowance increased due to increase in manpower, gratuity payment and salary revision.

ii) Travelling & conveyance increased during the period due to increase travel.

iii) Market Survey & Research and Product development expense increased due to increase in survey related works

iv) Field personnel expense increase due to increased of field personnel movement in order to increase sales.

v) Sample, Literature & Promotional Expenses increased in order to increase sales.

vi) Delivery expense during the reporting period increased due to increase in fuel and gas cost and vehicles rent cost.

vii) Depreciation expense during the reporting period increased due to increase addition of fixed assets .

27. WORKERS' P.P FUND & WELFARE FUND :	**15,845,655**	**15,041,661**
27.A CONSOLIDATED WORKERS' P.P. FUND & WELFARE FUND		
The IBN SINA Pharmaceutical Industry PLC	15,845,655	15,041,661
The IBN SINA Natural Medicine Ltd.	1,082,531	1,058,034
	16,928,186	**16,099,695**
28. INCOME TAX EXPENSES:		
Current Tax	84,865,791	87,111,047
Deferred Tax (income)/expense-note-19	(9,295,129)	(1,650,539)
	75,570,662	**85,460,508**

Reconciliation of Effective Tax Rate

Types of income	Income	Effective Tax Rate	Tax
Capital Gain	-	20.00%	-
Business Income	316,913,107	20.00%	63,382,621
	316,913,107	20.00%	63,382,621
Non Deductible Expenses		6.78%	21,483,169
Deferred Tax (income)/expense		-2.93%	(9,295,129)
		23.85%	75,570,662

28.A CONSOLIDATED INCOME TAX EXPENSES:		
Current Tax	91,347,924	93,737,976
Deferred Tax income/(expense) (note 19 A)	(5,319,679)	(1,740,639)
	86,028,245	**91,997,337**

Reconciliation of Effective Tax Rate

Types of income	Income	Effective Tax Rate	Tax
Capital Gain	-	20.00%	-
Business Income	324,770,464	20% to 27.50%	68,581,700
	324,770,464	21.12%	68,581,700
Non Deductible Expenses		7.01%	22,766,223
Deferred Tax (income)/expense		-1.64%	(5,319,679)
		26.49%	86,028,245

29. CHANGE IN FVOCI FINANCIAL ASSETS:		
Closing value of marketable securities	(22,860,303)	(20,576,153)
Opening value of marketable securities	(22,790,788)	(17,271,479)
	(69,515)	(3,304,674)

		Amount in Taka	
		From 1 July 2026 to 30 September 2026	From 1 July 2025 to 30 September 2025
30.	**Basic earnings per share has been calculated as follows :**		
	Earnings attributable to the Ordinary Shareholders (Net profit after tax)	241,342,445	215,372,712
	Divided by number of Ordinary Shares outstanding during the year/period	31,243,627	31,243,627
		7.72	**6.89**
30 A.	**CONSOLIDATED EARNINGS PER SHARE (EPS) :**		
	Basic earnings per share has been calculated as follows :		
	Earnings attributable to the Ordinary Shareholders (Net profit after tax)	239,252,653	221,226,529
	Divided by number of Ordinary Shares outstanding during the year/period	31,243,627	31,243,627
		7.66	**7.08**
31.	**NET ASSETS VALUE PER SHARE (NAV) :**		
	Net Assets Value	4,761,423,144	4,520,143,263
	Divided by number of Ordinary Shares outstanding during the period	31,243,627	31,243,627
		152.40	**144.67**

Net Assets Value Per Share (NAV) increased during the period due to increase in sales, maintaining stable expenses growth and increase in retained earnings.

31 A.	**CONSOLIDATED NET ASSETS VALUE PER SHARE (NAV):**		
	Net Assets Value	4,894,528,625	4,655,848,970
	Less: Non Controlling Interest	(138,730,289)	(139,240,723)
	Equity Attributable to the owners of the company	4,755,798,337	4,516,608,247
	Divided by number of Ordinary Shares outstanding during the year	31,243,627	31,243,627
		152.22	**144.56**
32.	**NET OPERATING CASH FLOWS PER SHARE (NOCFPS):**		
	Net cash provided by operating activities	6,900,085	168,222,825
	Divided by number of Ordinary Shares outstanding during the period	31,243,627	31,243,627
		0.22	**5.38**
32 A.	**CONSOLIDATED NET OPERATING CASH FLOWS PER SHARE (NOCFPS):**		
	Net cash provided by operating activities	13,450,360	170,647,320
	Divided by number of Ordinary Shares outstanding during the period	31,243,627	31,243,627
		0.43	**5.46**
33.	**RECONCILIATION OF NET PROFIT WITH CASH FLOWS FROM OPERATING ACTIVITIES:**		
	Profit before tax (PBT)	316,913,107	300,833,220
	Adjustment		
	Depreciation	45,887,147	48,107,501
	Deferred Tax	(9,302,080)	(1,981,006)
	Unrealized foreign exchange loss	(141,622)	(2,715,767)
	Change in operating assets		
	Increase in inventory	(23,190,273)	(30,689,267)
	Increase in accounts receivables	(58,985,002)	(602,211)
	Decrease in advances, deposits and prepayments	7,768,928	1,561,327
	Increase/(decrease) in trade and other payable	(187,213,098)	(99,244,092)
	Increase/(decrease) in retirement benefit obligation	1,401,106	956,411
	Tax paid during the year	(50,136,034)	(21,296,605)
	Finance charge	(36,102,094)	(26,706,687)
		6,900,085	**168,222,825**
34.	**FINANCE CHARGE:**		
	Finance charge for long term finance.	36,052,701	26,155,287
	Finance charge for lease	49,393	551,400
		36,102,094	**26,706,687**

Amount in Taka

	From 1 July 2026 to 30 September 2026	From 1 July 2025 to 30 September 2025
34.A CONSOLIDATED FINANCE CHARGE:		
Finance charge for long term finance.	36,052,701	26,155,287
Finance charge for lease	49,393	551,400
	36,102,094	**26,706,687**

35 RELATED PARTY DISCLOSURE:

Name of party	Relationship	Nature of transaction	Transaction		Sept' 2026	June 2026
			Dr.	Cr.	Receivable/(Payable)	
The IBN SINA API Industry Ltd.	Subsidiary (99.99%)	Acquisition of share Capital		40,000,000	839,999,800	799,999,800
The IBN SINA Natural Medicine Ltd.	Subsidiary (99.99%)	Acquisition of share Distribution Expense	17,084,926	-	238,169,670 -	238,169,670
The IBN SINA Polymer Industry Ltd.	Subsidiary (65%)	Acquisition of share Capital		60,000,000	-	-

35.01. NON-CONTROLLING INTEREST

	Profit Amount	NCI (%)	Net/Loss Amount
The IBN SINA API Industry Ltd.	(16,628,858)	0.000050	(8.31)
The IBN SINA Natural Medicine Ltd.	15,297,835	0.001260	193
The IBN SINA Polymer Industry Ltd.	(1,458,911)	35.000000	(510,619)
	(2,789,934)		(510,434)

Chief Financial Officer | Company Secretary | Director

Managing Director | Chairman

Dated, Dhaka .
08 November 2026